EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY 4.0

Favorable safety outcomes of a perioperative propranolol and etodolac regimen in cancer patients in four randomized controlled trials

Günstige Sicherheitsresultate eines perioperativen Propranolol- und Etodolac-Regimes bei Krebspatient:innen in vier randomisierten kontrollierten Studien

Nahida Sakis, Liat Sorski, Eden Asraf, Itay Ricon-Becker, Lee Shaashua, Rita Haldar, Bar Bruno Shvalbo, Maytal Shabat-Simon, Mordechai Gutman, Aviram Nissan, Ido Nachmany, Ilan Kent und 17 weitere

Frontiers in Pharmacology · 20.04.2026 · 17

DOI: 10.3389/fphar.2026.1823113 ↗

Auf einen Blick

In vier RCTs mit 148 Patient:innen war ein perioperatives Propranolol- und Etodolac-Regime insgesamt mit günstigen Sicherheitsresultaten verbunden. Bradykardie trat unter Behandlung häufiger auf, andere unerwünschte Ereignisse nicht signifikant anders.

Fragestellung

Wie sicher ist ein perioperatives Regime mit Propranolol und Etodolac bei Krebspatient:innen?

Methode

Vier RCTs mit Brust-, Kolorektal- und Pankreaskrebs; Beginn 5 Tage präoperativ, Fortführung 5–30 Tage postoperativ; primäre Endpunkte waren Sicherheitsoutcomes bis 30 Tage und 16 Blutwerte.

Ergebnisse

148 Patient:innen: Brustkrebs n = 38, Kolorektalkrebs n = 34 und n = 46, Pankreaskrebs n = 30. Bradykardie: 12 % unter Behandlung vs. 3 % unter Placebo (p = 0,057).

Einschränkungen

Explorative DFS-Analyse bei CRC war unterpowert; Effekte nach FDR-Korrektur nicht mehr signifikant.

Schlussfolgerung der Autor:innen

Die Autor:innen folgern, dass das perioperative Propranolol- und Etodolac-Regime in diesen RCTs sicher war.

Kernaussagen

  • Bradykardie häufiger unter Behandlung: 12 % vs. 3 %
  • Andere AEs nicht signifikant beeinflusst
  • Explorative DFS-Verbesserung bei CRC, aber unterpowert

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Klinische Studie in der Zeitschrift Frontiers in Pharmacology, online erschienen am 20.04.2026. Verfasst von Nahida Sakis und 28 weiteren Autor:innen. Beteiligte Einrichtung: School of Psychological Sciences, Tel Aviv University, Tel Aviv, Israel. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The perioperative use of the β-adrenergic blocker, propranolol, and/or the semi-selective COX-2 inhibitor, etodolac, has improved biomarkers of cancer metastasis in several small randomized controlled trials (RCTs). In colorectal cancer (CRC) patients, the combined regimen showed potential to improve disease-free survival (DFS).

Methods

We report data from our four RCTs including 148 patients with breast (n = 38), colorectal (n = 34 & n = 46), and pancreatic (n = 30) cancers. Treatment began 5 days pre-operatively, and continued for 5–30 postoperatively. Propranolol (slow-release) was initiated at 20 mg twice daily (b.i.d), increased to 80 mg b.i.d on surgery day, and gradually decreased thereafter to 20 mg b.i.d. Etodolac was provided at 400 mg b.i.d. The primary endpoints were perioperative safety outcomes, including adverse events (AEs) up to 30-day postoperatively, and 16 blood indices. Secondary outcomes were long-term oncological outcomes of 8-year DFS and overall survival (OS).

Results

Bradycardia occurred in 12% of treated vs. 3% of placebo patients (p = 0.057), and was easily resolved by temporary withholding β-blockade. Weakness, nausea, pain, infection, bleeding, leakage, tissue-healing, or death were not significantly affected. Drug treatment promoted eosinophils in pancreatic cancer patients (p = 0.015), increased potassium (p = 0.013), and decreased albumin (p = 0.016) in CRC patients; however, these effects did not remain significant after false discovery rate (FDR) correction. In CRC, treatment improved 8-year DFS (2/15 vs. 9/18, p = 0.034), although this exploratory analysis was underpowered.

Conclusion

These findings suggest the safety of this inexpensive and easy-to-implement perioperative propranolol and etodolac regimen in patients participating in these RCTs. Clinical Trial Registration https://clinicaltrials.gov/study/NCT00502684 , https://clinicaltrials.gov/study/NCT00888797 , https://clinicaltrials.gov/study/NCT03919461 , https://clinicaltrials.gov/study/NCT03838029 , identifier NCT00502684, NCT00888797, NCT03919461, NCT03838029.

Schlagwörter

Stichwörter der Autor:innen

COX2 inhibitorsetodolacmetastatic diseasenon-selective B-blockersperioperative carepropranololrandomized controlled trialsafety

Autor:innen und Institutionen

  • School of Psychological Sciences, Tel Aviv University, Tel Aviv, Israel.
  • Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel.
  • Department of Surgery and Transplantation, Sheba Medical Center, Ramat Gan, Israel.
  • Department of Surgical Oncology, Sheba Medical Center, Ramat Gan, Israel.
  • Department of General Surgery, Sheba Medical Center, Ramat Gan, Israel.
  • Department of General Surgery, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.

Zitieren

APA

Sakis, N., Sorski, L., Asraf, E., Ricon-Becker, I., Shaashua, L., Haldar, R., Shvalbo, B. B., Shabat-Simon, M., Gutman, M., Nissan, A., Nachmany, I., Kent, I., Pery, R., Pencovich, N., Shussman, N., Wasserberg, N., Reshef, A., Quint, E., Lishtzinsky, Y. Y., …, & Ben-Eliyahu, S. (2026). Favorable safety outcomes of a perioperative propranolol and etodolac regimen in cancer patients in four randomized controlled trials. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1823113

Vancouver

Sakis N, Sorski L, Asraf E, Ricon-Becker I, Shaashua L, Haldar R, et al. Favorable safety outcomes of a perioperative propranolol and etodolac regimen in cancer patients in four randomized controlled trials. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1823113

BibTeX
@article{Sakis2026,
  author = {Sakis, Nahida and Sorski, Liat and Asraf, Eden and Ricon-Becker, Itay and Shaashua, Lee and Haldar, Rita and Shvalbo, Bar Bruno and Shabat-Simon, Maytal and Gutman, Mordechai and Nissan, Aviram and Nachmany, Ido and Kent, Ilan and Pery, Ron and Pencovich, Niv and Shussman, Noam and Wasserberg, Nir and Reshef, Avraham and Quint, Elchanan and Lishtzinsky, Yifat Yosef and Kashtan, Hanoch and Shabtai, Moshe and Brenner, Baruch and Sharon, Eran and Allweis, Tanir and Shahar, Nitzan and Eckerling, Anabel and Sandbank, Elad and Zmora, Oded and Ben-Eliyahu, Shamgar},
  title = {Favorable safety outcomes of a perioperative propranolol and etodolac regimen in cancer patients in four randomized controlled trials},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1823113}
}
Kostenlos starten →